Literature DB >> 19901342

Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Chris K Grant1, Elizabeth A Fink, Magnus Sundstrom, Bruce E Torbett, John H Elder.   

Abstract

We analyzed antibody responses in sera from feline immunodeficiency virus (FIV)-infected and uninfected cats. A strong antiviral response to the viral surface glycoprotein (SU) was noted in both natural and experimental infections. In addition, 143 of 226 FIV-infected animals (63%) also expressed antibodies to the primary binding receptor, CD134, whereas cats infected with other feline RNA viruses, including calicivirus, coronavirus, herpesvirus, and feline leukemia virus, did not. Both affinity-purified anti-CD134 and anti-SU antibodies blocked FIV infection ex vivo. FACS analyses revealed that the anti-CD134 antibodies bound to a cryptic epitope on the receptor that was only exposed when SU bound to CD134. Anti-CD134 binding caused displacement of SU from the surface of the cell and inhibition of infection. The presence of antibodies to CD134 correlated with lower virus loads and a better overall health status in FIV(+) cats, whereas anti-SU antibodies were present independent of health status. The findings are consistent with a role for antireceptor antibodies in protection from virus spread and disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901342      PMCID: PMC2775039          DOI: 10.1073/pnas.0911307106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Immunopathologic changes in the thymus during the acute stage of experimentally induced feline immunodeficiency virus infection in juvenile cats.

Authors:  J C Woo; G A Dean; N C Pedersen; P F Moore
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats.

Authors:  L L O'Neil; M J Burkhard; E A Hoover
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 3.  The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus.

Authors:  B J Willett; M J Hosie
Journal:  Mol Membr Biol       Date:  1999 Jan-Mar       Impact factor: 2.857

4.  Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR.

Authors:  T R Phillips; O Prospero-Garcia; D W Wheeler; P C Wagaman; D L Lerner; H S Fox; L R Whalen; F E Bloom; J H Elder; S J Henriksen
Journal:  J Neurovirol       Date:  1996-12       Impact factor: 2.643

5.  Histopathological changes in lymph nodes of cats experimentally infected with the feline immunodeficiency virus (FIV).

Authors:  A L Parodi; F Femenia; A Moraillon; F Crespeau; J J Fontaine
Journal:  J Comp Pathol       Date:  1994-08       Impact factor: 1.311

6.  Sleep patterns are disturbed in cats infected with feline immunodeficiency virus.

Authors:  O Prospéro-García; N Herold; T R Phillips; J H Elder; F E Bloom; S J Henriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Maternal-fetal feline immunodeficiency virus transmission: timing and tissue tropisms.

Authors:  A B Rogers; E A Hoover
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

8.  Pharmacology of ethanol and glutamate antagonists on rodent sleep: a comparative study.

Authors:  O Prospero-García; J R Criado; S J Henriksen
Journal:  Pharmacol Biochem Behav       Date:  1994-10       Impact factor: 3.533

9.  Vertical transmission of feline immunodeficiency virus.

Authors:  L L O'Neil; M J Burkhard; L J Diehl; E A Hoover
Journal:  AIDS Res Hum Retroviruses       Date:  1995-01       Impact factor: 2.205

10.  Early stages of feline immunodeficiency virus infection in lymph nodes and spleen.

Authors:  J M Bach; M Hurtrel; L Chakrabarti; J P Ganiere; L Montagnier; B Hurtrel
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

View more
  7 in total

1.  Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection.

Authors:  Britta A Wood; Scott Carver; Ryan M Troyer; John H Elder; Sue VandeWoude
Journal:  J Immunol Methods       Date:  2013-08-14       Impact factor: 2.303

2.  Prevalence of autoantibodies that bind to kidney tissues in cats and association risk with antibodies to feline viral rhinotracheitis, calicivirus, and panleukopenia.

Authors:  Nisakorn Songaksorn; Wilaiwan Petsophonsakul; Kidsadagon Pringproa; Kannika Na Lampang; Nattawooti Sthitmatee; Nuttawan Srifawattana; Kakanang Piyarungsri; Kriangkrai Thongkorn
Journal:  J Vet Sci       Date:  2021-05       Impact factor: 1.672

Review 3.  The molecular biology of feline immunodeficiency virus (FIV).

Authors:  Julia C Kenyon; Andrew M L Lever
Journal:  Viruses       Date:  2011-11-09       Impact factor: 5.048

Review 4.  The virus-receptor interaction in the replication of feline immunodeficiency virus (FIV).

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Curr Opin Virol       Date:  2013-08-28       Impact factor: 7.090

5.  Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.

Authors:  Elizabeth Fink; Katherine Fuller; Brian Agan; Edward A Berger; Andrew Saphire; Gerald V Quinnan; John H Elder
Journal:  AIDS Res Hum Retroviruses       Date:  2016-11-21       Impact factor: 2.205

6.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Authors:  Craig Miller; Mauren Emanuelli; Elizabeth Fink; Esther Musselman; Ryan Mackie; Ryan Troyer; John Elder; Sue VandeWoude
Journal:  NPJ Vaccines       Date:  2018-04-30       Impact factor: 7.344

Review 7.  Virus-host interaction in feline immunodeficiency virus (FIV) infection.

Authors:  Sueli Akemi Taniwaki; Andreza Soriano Figueiredo; João Pessoa Araujo
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2013-08-02       Impact factor: 2.268

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.